Workaround erases side effects of promising cell-based cancer therapy

March 2, 2018 by Bruce Goldman, Stanford University Medical Center
Workaround erases side effects of promising cell-based cancer therapy
Research at Stanford are looking at whether a type of immune cell known as a T cell could be taken from a cancer patient, then modified and returned to the patient to destroy tumors. Credit: Wikipedia

Stanford scientists created an odd couple: a modified version of an immune-signaling protein and a coordinately modified receptor for this protein. The two bind only to each other, easing an advanced anti-cancer therapy's side effects.

Altering a powerful immune-signaling chemical plus its receptor on immune may bring a promising cancer treatment closer to the clinic, according to a study led by investigators at the Stanford University School of Medicine.

If the advance proves as beneficial in humans as in mice used in the study, which was conducted in collaboration with researchers at the University of California-Los Angeles and UC-San Francisco, then incorporating it into the experimental regimen, called adoptive cell transfer, could speed that treatment's acceptance as a standard anti-cancer practice.

In adoptive cell transfer, called killer T cells are purified from a patient's blood, endowed with superior tumor-recognition features via genetic engineering, and induced to proliferate. The modified cells are returned to the patient's circulatory system, where they can efficiently and selectively destroy tumors.

But this approach is hampered by the modified T cells' failure to continue to survive, multiply and sustain their targeted rampage for substantial amounts of time after they've been transferred back into the patient. That's because the altered T cells need frequent "booster shots" of a crucial protein called interleukin-2, or IL-2, just as natural T cells do.

"IL-2 is a master regulator of the immune system and, in particular, the principal T-cell growth factor," said Christopher Garcia, Ph.D., professor of molecular and cellular physiology and of structural biology, and a Howard Hughes Medical Institute investigator. "It's responsible for T cells' development, expansion and activation."

Garcia is the senior author of the multidisciplinary study, published March 2 in Science. The lead author is former postdoctoral scholar Jonathan Sockolosky, Ph.D.

Secreted in response to threats

Produced naturally by various types of immune cells, IL-2 is secreted in response to various threats. When it binds to receptors on T cells' surfaces, including receptors on the T cells secreting it, it spurs them to action. Deprived of this booster substance, once-active T cells become inhibited, exhausted and, ultimately, burnt out.

This applies to the modified T cells infused into cancer patients, said Garcia, who holds the Younger Family Professorship. "These bioengineered T cells need IL-2 to survive, to work and to expand in number, just as our natural ones do," he said.

That's fine when the T cells are outside the patient's body. But strategies to boost the efficacy of adoptive cell transfer approaches by following up T cell infusion with intravenous IL-2 administrations have had major limitations. The reason is that the side effects provoked by substantial doses of the powerful protein—especially pulmonary edema—are so severe as to outweigh the advantages of the treatment.

The problem is that receptors for IL-2 are found not only on T cells but other immune cells that are better left inactive during cancer therapy—for instance, so-called regulatory T cells whose job is to mute the immune response after the immune system has been mobilized against a tumor or invading pathogen. Failure of the immune system to stand down can spell constant tissue-damaging inflammation and autoimmune disease. Many other types of cells in the body, such as lung cells, also harbor IL-2 receptors, Garcia said, and IL-2 can induce damaging inflammation to the tissues containing those cells.

But Garcia and his research group have found a workaround that should allow adoptive cell transfer to proceed without burnout—and without IL-2's devastating side effects.

Tweaking IL-2

"We engineered a slightly tweaked version of one of IL-2's constituent subunits so that a receptor containing this subunit can no longer bind to IL-2," he said. "And we generated a slightly altered IL-2 molecule that can't bind to its normal receptor." But the modified protein and modified receptor bind with high affinity to one another. Garcia credited Sockolosky for the meticulous matchmaking that paired up this auspicious odd couple.

Using laboratory methods to snap the modified receptors onto T cells from mice, Garcia's group showed in a series of experiments that these T cells responded to modified IL-2 exactly as natural T cells would be expected to respond to ordinary IL-2. But unmodified T cells didn't respond to the modified IL-2 at all.

Next, Garcia's team and colleagues turned to the laboratories of two of the study's co-authors, UCSF immunologist Jeffrey Bluestone, Ph.D., and UCLA cancer specialist Antoni Ribas, MD. There, further disease-based experiments were conducted, including some with mice in which a well-characterized type of melanoma had been induced. Mice burdened by this highly aggressive tumor ordinarily die quickly. Adoptive cell therapy—the infusion of the mice's own T cells after they'd been bioengineered to target that specific tumor type—followed by regular IL-2 infusions was able to arrest growth in these melanomas, but the IL-2 caused a plethora of nasty side effects mirroring those of its administration in humans: weight loss, restricted mobility, hypothermia, enlarged spleen and lymph glands, and probable death. (Mice in the study were euthanized if they became sick to the point of likely death.)

However, when T cells similarly bioengineered to attack the tumors, as well as outfitted with modified receptors responsive only to the tweaked version of IL-2, were infused into the mice and bolstered with regular doses of tweaked IL-2, they also shrunk the tumors—but without side effects. These mice's survival was significantly improved in comparison with either untreated mice or those receiving adoptive cell transfer absent IL-2.

"Adoptive cell therapy is on the cusp of becoming a revolutionary new approach to cancer treatment," said Garcia. "It's undergoing explosive growth—it's a multibillion-dollar biotechnology industry already, and it's going to become as routine as bone marrow transplants are now. But all of the approaches in development today need IL-2, so new and better ways of delivering IL-2 are a critical unmet need. Our approach is also applicable to other important immune substances and cell types."

Garcia said his group has now generated human odd-couple IL-2/receptor pairs that, like their mouse counterparts, bind only to one another. He is looking for collaborators in academia or industry to launch a clinical trial based on the new technology. And, he said, he believes the same approach, employed to stimulate regulatory T cells rather than killer T cells, should in principle be effective in combatting autoimmune disease. Bluestone and another study co-author, postdoctoral scholar Eleonora Trotta, Ph.D., are working on that approach at UCSF, Garcia noted.

Explore further: Hunting for immune cells' cancer targets

Related Stories

Hunting for immune cells' cancer targets

December 21, 2017
By screening millions of molecular targets, researchers have uncovered a tumor beacon detected by the immune cells of two patients with colorectal cancer.

New technique could reveal immunotherapy targets, study finds

December 21, 2017
Researchers at the Stanford University School of Medicine and their colleagues have developed a way to pinpoint potential targets for cancer therapies that rely on the body's immune system.

Universal donor immune cells

July 25, 2011
One of the latest attempts to boost the body's defenses against cancer is called adoptive cell transfer, in which patients receive a therapeutic injection of their own immune cells. This therapy, currently tested in early ...

Researchers uncover novel mechanism by which tumors evade cancer immunotherapies

November 10, 2017
A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumors of the aggressive skin cancer melanoma can resist cancer immunotherapy. Their paper, ...

'Super T cells' engineered for optimal performance drive new gene-therapy approach

November 3, 2017
Researchers at Roswell Park Cancer Institute have initiated a clinical trial based on a unique two-pronged strategy for arming the immune system to more effectively attack cancer cells. Patients treated through this early-stage ...

New approach in T-cell therapy to treat cancer

June 8, 2017
Scientists have armed immune cells with a new surface molecule. This causes the cells to respond particularly aggressively when they encounter a protein that tumors actually use to camouflage themselves from the immune system. ...

Recommended for you

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.